There is no cure for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and the CDC says there is no approved treatment and no test to confirm it. Its defining symptom is post-exertional malaise: symptoms get worse after physical or mental effort, often a day or two later. The CDC estimates up to 3.3 million people in the U.S. have it. Care today means pacing activity to stay within energy limits and treating symptoms such as dizziness on standing, poor sleep and pain. Our view: a cure will need a clear biological target, and recent genetic, immune-cell and muscle studies are starting to point to some. No drug has yet proven itself in a large trial.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Care decisions belong with a medical team experienced in ME/CFS.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your doctor experienced in ME/CFS.
Could a lab test of what a person's antibodies do, such as whether they disturb cells in a dish, find an antibody-driven form of ME/CFS better than antibody levels can? No such test exists yet for patient care. And could lowering harmful antibodies in only those people bring lasting improvement that whole-group trials missed? Antibody filtering and B-cell drugs are experimental for ME/CFS, so this should only be tested in controlled trials.
What would prove it wrong: if people picked by such a test improve no more than people given a sham or placebo in a controlled trial.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
Researchers re-analyzed public gene-activity data from people with ME/CFS and found SGK1 more active in a type of immune cell (monocytes and neutrophils). In lab-grown cells made to age, switching SGK1 down lowered markers of cell aging. This is early work built on existing datasets and cell experiments, not patients, and the authors say it needs testing in ME/CFS patients' own immune cells.
A University of Alabama at Birmingham Phase 2 trial will compare 1.5, 3.0 and 4.5 mg doses in about 75 people, run remotely for Alabama residents. The registry lists it as not yet recruiting, with an estimated start of October 1, 2026.
A scoping review of 190 papers found that most studies measure illness severity and burden with general tools such as the SF-36 and Sickness Impact Profile. Disease-specific tools such as the DePaul Symptom Questionnaire are used less. The authors say general tools can miss key symptoms like post-exertional malaise and that standard measures are needed. This is a review of methods, not a treatment finding.
Solve ME/CFS reports that the CDC draft for the 2028 National Health Interview Survey leaves out questions on ME/CFS, long COVID and fatigue. That survey produced the U.S. adult ME/CFS estimate for 2021-2022. This is a draft; the CDC has said topics can still be added. Advocacy-group report; we have not seen the CDC document.
A meta-analysis of 15 randomized trials (2,270 people with chronic fatigue syndrome) found that cognitive behavioral therapy (CBT) lowered fatigue and slightly improved physical function after treatment, with benefits still seen at 6 to 24 months. The authors conclude CBT "may be an effective option" and call for more research. This is a pooled analysis of existing trials and is not a cure; the reported benefit is modest.
In 40 adolescents aged 10 to 17, 89% had missed school because of illness and 64% had home or homeschool instruction. Post-exertional malaise, unrefreshing sleep and fatigue were common. Core features looked similar to adults, though adults reported more physical symptoms. It describes the illness at one point in time and tests no treatment.
Researchers combined published genetic data with 3D genome maps for long COVID, ME/CFS, PTSD, rheumatoid arthritis and MS. Few single genes overlapped, but the conditions converged on shared networks for immunity, metabolism and cell energy. It was a computer analysis of existing data, not a patient trial, and the candidate genes still need testing. The research team includes staff from Oxford BioDynamics, which sells the method used.
In registry data from 736 people with physician-diagnosed ME/CFS, muscle problems were linked to breathing difficulties, flu-like symptoms, temperature-regulation problems and heart-related symptoms. The authors say these fit one shared pattern of body-system disruption. It is a cross-sectional analysis, so it cannot show cause.
Researchers compared patients with healthy people after 60 days of strict bed rest. Both patient groups had more fast-tiring (glycolytic) muscle fibers, and people with ME/CFS had shrinkage of slow-twitch fibers. Bed rest did not produce the same pattern, so inactivity alone can't explain the patients' lower exercise capacity.
In spinal-fluid tests at the NIH Clinical Center, people with post-infectious ME/CFS and long COVID had lower activity in the brain's noradrenaline pathway than healthy volunteers, with no difference in dopamine. Lower activity was linked to more fatigue.
In an open-label trial of 91 people with ME/CFS and low vitamin D, adding vitamin D supplements plus diet, sun and activity guidance reduced symptom counts more than an active vitamin D drug alone over 12 weeks. It was small, unblinded and limited to people with low vitamin D after COVID-19 or vaccination.
Two separate labs tested immune (natural killer) cells from 36 people with ME/CFS and 42 healthy controls. TRPM3 channel function was lower in ME/CFS on every measure, with no difference between labs. The authors see it as a possible diagnostic marker.
A 200-marker blood test separated 47 people with severe ME/CFS from 61 healthy controls with 92% sensitivity and 98% specificity in a first validation. Most authors work for the company that makes the test, and it has not been tested in large, independent groups.
The largest genetic study of ME/CFS (15,579 cases, 259,909 controls) found 8 regions of DNA linked to the illness, several involved in responding to infection and one tied to chronic pain. Released as a preprint, not yet peer reviewed.
Data from up to 1,455 people with ME/CFS and 131,303 controls showed hundreds of blood traits differed, pointing to chronic inflammation, insulin resistance and liver stress. Only 1 of 3,237 traits was explained by low activity. No single trait could diagnose ME/CFS on its own.
A placebo-controlled, double-blind trial at Japan's National Center of Neurology and Psychiatry aims to enroll about 30 people with ME/CFS. It is recruiting, with primary completion estimated for September 2026.
A Phase 2 trial at Brigham and Women's Hospital in about 160 people with ME/CFS and orthostatic intolerance, and people with long COVID. It is recruiting, with primary completion estimated for September 2026.
An intensive NIH study found immune signs of long-term stimulation (more naive and fewer switched memory B cells), differences in brain catecholamine pathways and autonomic function, and gene-expression differences that varied by sex.
In 151 people in Norway, response rates were 26.0% with rituximab and 35.1% with placebo, with no difference in fatigue over 24 months. Serious side effects were more common with rituximab (26.0% vs 18.9%).
No drug is approved for ME/CFS in the U.S. What helps today is managing energy and treating individual symptoms. Drug trials are still small and early.
Learning your own limits for physical and mental activity and planning activity and rest to stay within them, to avoid post-exertional malaise flare-ups. It manages symptoms; it is not a cure.
The CDC lists raising blood volume (for people without heart or blood-vessel disease), lying down or sitting with feet on the floor, sitting in the shower, keeping cool and compression garments. Medicines can follow, ideally overseen by an expert.
Personal sleep advice, then low-dose sleep medicine if needed. For pain, simple pain relievers first, plus heat, gentle massage or stretching done carefully to avoid a crash. NICE advises starting medicines at lower doses.
An immune-modulating drug given by infusion. Argentina's regulator approved it for severe ME/CFS in August 2016, according to the company. The FDA has not approved it.
A low dose of an older approved drug, used off-label by some doctors. It is being tested in controlled trials for ME/CFS, alone or with pyridostigmine. Results from these trials are not yet available.
This B-cell–depleting drug did not improve fatigue or function compared with placebo, and caused more serious side effects. A small Phase 2 trial in Japan is testing it again in selected patients.
| Treatment | For | What it does |
|---|---|---|
| Pacing / energy management | Everyone with ME/CFS | Balances activity and rest to reduce post-exertional malaise. |
| Orthostatic intolerance care | Dizziness or racing heart when upright | Fluids and blood-volume support, positioning, compression; medicine if needed. |
| Sleep management | Unrefreshing or broken sleep | Personal sleep advice; sleep medicine at the lowest dose if needed. |
| Pain relief | Headache, muscle and joint pain | Simple pain relievers and gentle non-drug methods; pain specialist if needed. |
| Cognitive behavioural therapy (optional) | People who want support coping | NICE says it may help manage symptoms and distress but is not a cure, and should only be offered if the person wants it. |
NICE says no medicine or supplement cures ME/CFS. The most useful daily tools are about managing energy and symptoms. We rate each by the strength of evidence.
Recommended by both NICE and the CDC. Staying within your energy limits helps avoid post-exertional malaise.
NICE advises sleep advice tailored to the person, balancing daytime rest. The CDC notes some standard sleep rules (such as no daytime naps) don't suit people who are bedbound.
NICE notes people with ME/CFS, especially if housebound, may be at risk of low vitamin D. A small 2026 trial in Japan showed benefit in people who were low. Get levels checked first.
The CDC lists these for pain, with care to avoid triggering a crash. It says acupuncture by a licensed practitioner might help pain for some.
NICE says not to offer any medicine or supplement to cure ME/CFS.
NICE says there isn't enough evidence for routine vitamin or mineral supplements, and doses above daily recommended amounts can cause side effects.
The CDC says standard exercise advice for healthy people can be harmful in ME/CFS. NICE says not to offer exercise as a cure or programs with fixed step-by-step increases.
Be careful: symptoms can worsen a day or two after too much activity, so a good day isn't a sign to do more. Tell your doctor about every supplement you take, since people with ME/CFS can be more sensitive to medicines, and check new or worsening symptoms with a doctor rather than assuming they are ME/CFS.
Centers recognized for expertise in this condition, and communities of people living with it.
A clinic dedicated to ME/CFS, long COVID and fibromyalgia, and the listed site of registered ME/CFS trials, including a placebo-controlled trial of oxaloacetate.
Runs LIFT, a registered Phase 2 trial of pyridostigmine and low-dose naltrexone in people with ME/CFS and orthostatic intolerance.
Site of a registered Phase 2 trial of N-acetylcysteine in ME/CFS. Cornell University also holds an NIH grant (U54AI178855, 2023) for its ME/CFS Collaborative Research Center, a research program rather than a clinic.
A specialist fatigue center at Charité university hospital and the site of registered trials of vericiguat in post-COVID ME/CFS and inebilizumab in post-infectious ME/CFS.
Runs a registered placebo-controlled Phase 2 trial of rituximab in ME/CFS.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
Living with ME/CFS can be isolating, and other people with it understand. Many people with moderate or severe ME/CFS can't travel, so online and phone support matter most. Most of these are free.
A patient advocacy network with a "Find Your Group" support-group finder, a doctor locator, crisis resources and the yearly #MillionsMissing campaign.
Visit ↗Funds ME/CFS research, runs the unhide patient registry, and offers patient stories, provider directories and advocacy tools.
Visit ↗Runs the ME Connect helpline six days a week, lists local support groups, and keeps a directory of NHS specialist ME/CFS services.
Visit ↗Offers free support services, the ME Friends Online peer forum, and a young people's community with free counselling.
Visit ↗A national charity with a nurse-staffed telehealth support line, online education sessions and support groups.
Visit ↗Many private patient and carer groups exist. This link searches Facebook (a login is required).
Search Facebook ↗Before you join: support groups share experiences, not medical advice. Check anything about treatment with your doctor, and be wary of anyone selling a "cure" for ME/CFS. Protect your privacy, and never share passwords or financial details. Online groups can be draining, so pace screen time like any other activity. Cure Checker isn't affiliated with these groups.
Care everywhere is built on managing energy and symptoms. The only drug approval for ME/CFS we could verify is rintatolimod in Argentina, which is not one of the countries in this table.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| Rintatolimod (Ampligen)Approved in Argentina only (2016), severe ME/CFS | Not approved | — | — | — | — | — | — | — | — |
| Pacing / energy managementStandard care | Used | — | Used | — | — | — | — | — | — |
| Graded exercise therapyFixed incremental increases | — | — | Not advised | — | — | — | — | — | — |
The company announced on August 23, 2016 that Argentina's regulator, ANMAT, approved rintatolimod for severe ME/CFS, the first approval for ME/CFS anywhere. It is not approved in the U.S.
A Phase 2a trial of the heart drug vericiguat in post-COVID ME/CFS is active, and a Phase 2b trial of the B-cell drug inebilizumab in post-infectious ME/CFS is planned to start in December 2026.
An exploratory, placebo-controlled rituximab trial is recruiting about 30 people, after the large 2019 Norwegian trial found no benefit.
The CDC says scientists don't yet know what causes ME/CFS. Leading ideas involve infections, immune changes, how cells make energy, and genes. It is a physical illness: studies keep finding measurable differences in the body.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
We found one organization that gives money directly to people with ME/CFS. Funds are limited and rules vary, so contact it directly.
One-time help with one essential cost, such as a rent payment, a utility bill or a medical copay. Grants are usually in the hundreds of dollars, there is no ongoing help, and households with a working adult can't apply. The page doesn't say whether the fund is open now, so ask by email first.
See the fund ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 4, 2026.
Not individually cited: that low-dose naltrexone is an older approved drug used off-label, that rintatolimod is given by infusion and acts on the immune system, and the plain descriptions of brain fog and sleep, which reflect the established medical literature. The rintatolimod approval in Argentina rests only on the company's own announcements; we could not open the Argentine regulator's (ANMAT) record. "Not approved" in the U.S. rests on the CDC's statement that there is no approved treatment, the company's 2019 filing, and no Drugs@FDA record. We report the graded exercise therapy question only from NICE and CDC wording; we could not find a CDC page that itself documents when earlier exercise and CBT advice was removed, so that history is left out. The DecodeME results are a preprint, and the EpiSwitch test study was largely written by employees of the company behind it. The vitamin D trial was open-label and the trial cards for NCT07285473 and NCT07724834 describe planned, not-yet-recruiting studies. All "—" cells in the approvals table are unverified. A Reddit ME/CFS community is not listed because we could not open Reddit to confirm it. Expert care centers: no official national center-of-excellence designation for ME/CFS could be verified for these sites. They are listed for registered trial roles (all five), plus an NIH research grant (Cornell); the Bateman Horne Center's description of its own clinic rests on its own website. Financial help: checked October 6, 2026. The AMMES fund page has no date or open/closed status, and its application form dates from 2018. Left out: #MEAction's Colorado emergency fund (its page no longer exists), the UK's M.E. Trust (closed in 2022), and charities that give only advice or fund research. We could not find an ME/CFS fund at HealthWell, and the PAN Foundation, Patient Advocate Foundation and The Assistance Fund blocked our checks.